TransMedics Group, Inc.
Income Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $605.5M | $438.26B | $264.18B | $76.48B | $11.44B | $3.04B | $0 | $0 |
| Product Revenue | — | $438.26B | $264.18B | $76.48B | $11.44B | $3.04B | $0 | $0 |
| Service Revenue | — | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cost of Revenue | $242.7M | $179.5M | $87.5M | $28.2M | $9.1M | $9.0M | $9.7M | $7.3M |
| Gross Profit | $362.8M | $262.1M | $154.1M | $65.3M | $21.2M | $16.6M | $13.9M | $5.7M |
| Gross Margin | 59.9% | 0.1% | 0.1% | 0.1% | 0.2% | 0.5% | — | — |
| Operating Expenses | ||||||||
| Research & Development | $69.1M | $56.0M | $36.1M | $26.8M | $22.3M | $18.8M | $19.9M | $13.7M |
| SG&A Expense | $185.2M | $168.6M | $119.6M | $69.9M | $38.3M | $24.2M | $23.6M | $12.3M |
| Operating Income | $108.6M | $37.5M | $-28.7M | $-31.4M | $-39.4M | $-26.4M | $-29.6M | $-20.2M |
| Operating Margin | 17.9% | 0.0% | 0.0% | 0.0% | -0.3% | -0.9% | — | — |
| Interest Expense | — | — | $10.8M | $3.7M | $3.9M | $4.0M | $4.4M | $2.7M |
| Pretax Income | $107.5M | $35.8M | $-26.7M | $-36.2M | $-44.2M | $-28.7M | $-33.5M | $-23.7M |
| Income Tax Expense | $-82.8M | $316.0K | $-1.6M | $66.0K | — | $0 | $0 | $0 |
| Net Income | $190.3M | $35.5M | $-25.0M | $-36.2M | $-44.2M | $-28.7M | $-33.5M | $-23.8M |
| Net Margin | 31.4% | 0.0% | 0.0% | 0.0% | -0.4% | -0.9% | — | — |
| EPS (Basic) | $5.60 | $1.07 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 | $-17.48 |
| EPS (Diluted) | $4.87 | $1.01 | $-0.77 | $-1.23 | $-1.60 | $-1.16 | $-2.36 | $-17.48 |
| Shares Outstanding (Basic) | 34.0M | 33.2M | 32.5M | 29.6M | 27.6M | 24.7M | — | — |
| Shares Outstanding (Diluted) | 40.5M | 35.2M | 32.5M | 29.6M | 27.6M | 24.7M | — | — |
| Dividends Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | — |